UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Boston Scientific Corporation
In a report published Wednesday, Citigroup reiterated its Buy rating on Boston Scientific Corporation (NYSE: BSX), and slightly raised its price target from $7.30 to $8.20.
Citigroup noted, “BSX's shares have moved up significantly faster than we expected since last Thanksgiving, but we still see room for the stock on a fundamental basis as trends are improving and the peer group valuation has moved up. Plus, we still believe the call option on Durata being removed from the market is largely underappreciated.”
Boston Scientific Corporation closed on Tuesday at $7.10.
Latest Ratings for BSX
|Feb 2015||Deutsche Bank||Maintains||Hold|
|Feb 2015||JP Morgan||Maintains||Overweight|
|Feb 2015||Stifel Nicolaus||Maintains||Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.